Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 4

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02333292Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Role: lead

NCT02057003Unknown

Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

Role: lead

NCT01908660Completed

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Role: lead

NCT01277627Not ApplicableUnknown

Influence of Nevirapine on HCV Viral Load

Role: lead

NCT00856804Phase 2Unknown

Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance

Role: lead

NCT00546442Phase 4Completed

Treatment Insulin Resistence in HCV G-1 Patient

Role: lead

All 6 trials loaded